Advice
following an abbreviated submission:
degarelix (Firmagon®) is accepted for use within NHSScotland.
Indication under review:
- for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
- as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
Degarelix offers an additional treatment choice in the therapeutic class of gonadotrophin releasing hormone (GnRH) antagonist/agonist in this setting.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice256KB (PDF)
Medicine details
- Medicine name:
- degarelix (Firmagon)
- SMC ID:
- SMC2625
- Indication:
- for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy
- as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer
- for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy
- Pharmaceutical company
- Ferring Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 December 2023